Product Details
PIOGLITAZONE HCL 15 MG + METFORMIN 500 (SR)
Introduction : The combination of Pioglitazone HCl 15mg + Metformin 500mg SR is indicated for the management of type 2 diabetes mellitus (T2DM) in adults when diet and exercise alone are not sufficient to achieve glycemic control.
Indication : Pioglitazone 15mg and Metformin 500mg SR (sustained release) tablet work together to lower blood sugar levels in individuals with type 2 diabetes. Pioglitazone enhances insulin sensitivity in peripheral tissues, while Metformin primarily reduces hepatic glucose production and improves insulin sensitivity.
Pioglitazone 15mg and Metformin 500mg SR (sustained release) tablet helps improve glycemic control by reducing fasting and postprandial blood glucose levels. It is particularly beneficial for patients with T2DM who have not achieved adequate blood sugar control with diet and exercise alone.
Administration : It is typically taken orally once or twice daily with meals or as directed by a healthcare professional. Or just before the meals
Storage : Store at room temperature away from moisture and heat.
Side Effects : Gastrointestinal disturbances such as nausea, vomiting, diarrhea, or abdominal discomfort
Headache
Weight gain (especially with pioglitazone)
Edema (fluid retention) in some patients
Hypoglycemia (low blood sugar levels) when used in combination with other antidiabetic medications
Contraindications : Avoid use of this drug during pregnancy and prescribe an alternative. Evidence has demonstrated fetal abnormalities or risks when used during pregnancy.
Evidence and/or expert consensus has demonstrated harmful infant effects when used during breastfeeding.
Safety Advice / Warnings : This medicine may increase the risk for bone fractures in women. Ask your doctor about ways to keep your bones strong to help prevent fractures.
Pioglitazone + Metformin should not be used in patients with type 1 diabetes mellitus or diabetic ketoacidosis.
Pioglitazone has been associated with an increased risk of bladder cancer, and patients should be monitored for signs and symptoms of bladder cancer during treatment.
Patients should be advised to adhere to a regular meal schedule and monitor blood sugar levels closely while taking this medication.
References : Product Information: ACTOS oral tablets, pioglitazone oral tablets. Takeda Pharmaceuticals America, Inc. (per FDA), Deerfield, IL, 2016.
Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2015
Mechanism of Action : Pioglitazone Hydrochloride 15mg: Pioglitazone is a thiazolidinedione (TZD) antidiabetic medication that improves insulin sensitivity in peripheral tissues such as muscle and adipose tissue. It acts as a selective agonist for peroxisome proliferator-activated receptor gamma (PPAR-?), enhancing glucose utilization and reducing hepatic glucose production.
Metformin 500mg SR (Sustained Release): Metformin is a biguanide antidiabetic drug that primarily reduces hepatic glucose production, enhances insulin sensitivity in peripheral tissues, and improves glucose uptake by muscles.
Therapeutic : Hypoglycemic agent